Abstract
Background Observational studies have linked childhood obesity with elevated risk of colorectal cancer, however, it is unclear if this association is causal or independent from the effects of obesity in adulthood on colorectal cancer risk.
Methods We conducted Mendelian randomization (MR) analyses to investigate potential causal relationships between self-perceived body size in early life (age 10) and measured body mass index in adulthood (mean age 56.5) with risk of colorectal cancer. The total and independent effects of body size exposures were estimated using univariable and multivariable MR, respectively. Summary data were obtained from a genome-wide association study of 453,169 participants in UK Biobank for body size and from a genome-wide association study meta-analysis of three colorectal cancer consortia of 125,478 participants.
Results Genetically predicted early life body size was estimated to increase odds of colorectal cancer (odds ratio [OR] per category change: 1.12, 95% confidence interval [CI]: 0.98-1.27), with stronger results for colon cancer (OR: 1.16, 95% CI: 1.00-1.35), and distal colon cancer (OR: 1.25, 95% CI: 1.04-1.51). After accounting for adult body size using multivariable MR, effect estimates for early life body size were attenuated towards the null for colorectal cancer (OR: 0.97, 95% CI: 0.77-1.22) and colon cancer (OR: 0.97, 95% CI: 0.76-1.25), while the estimate for distal colon cancer was of similar magnitude but more imprecise (OR: 1.27, 95% CI: 0.90-1.77).
Conclusions Our findings suggest that the positive association between early life body size and colorectal cancer risk is likely due to large body size retainment into adulthood.
Competing Interest Statement
Tom G Richardson is employed part-time by Novo Nordisk outside of the research presented in this manuscript. The remaining authors declare no competing interests.
Funding Statement
This work was supported by Cancer Research UK (C18281/A29019) MJ and DJH received funding from the International Hundred K+ Cohorts Consortium / Global Genomic Medicine Collaborative (IHCC/G2MC) No.31312020. C.J.B. is supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009). J.A.B. works in a unit funded by the UK MRC (MC_UU_00011/1) and the University of Bristol. E.E.V. is supported by Diabetes UK (17/0005587) and the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-20011), the MRC Integrative Epidemiology Unit (MC_UU_12013/3) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169). GDS works in a unit funded by the UK Medical Research Council (MC_UU_00011/1) and the University of Bristol. TGR and ES work within the Medical Research Council Integrative Epidemiology Unit at the University of Bristol (MC_UU_00011/1). TGR is a UKRI Innovation Research Fellow (MR/S003886/1). KKT is supported by Cancer Research UK (PPRCPJT\100005) Information on consortia funding is included in the supplementary material.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent, and each study was approved by the relevant research ethics committee or institutional review board. The paper proposal was approved by the Colorectal Cancer Consortia (GECCO; CCFR; CORECT) Coordinating Center
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data availability: The summary statistics used in this study are outlined in the supplementary materials. The summary-level GWAS data on outcomes used in this study are available following an application to the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). https://www.fredhutch.org/en/research/divisions/public-health-sciences-division/research/cancer-prevention/genetics-epidemiology-colorectal-cancer-consortium-gecco.html
Potential competing interests: Tom G Richardson is employed part-time by Novo Nordisk outside of the research presented in this manuscript. The remaining authors declare no competing interests.
Funding information: This work was supported by Cancer Research UK (C18281/A29019) MJ and DJH received funding from the International Hundred K+ Cohorts Consortium / Global Genomic Medicine Collaborative (IHCC/G2MC) No.31312020.
C.J.B. is supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009).
J.A.B. works in a unit funded by the UK MRC (MC_UU_00011/1) and the University of Bristol.
E.E.V. is supported by Diabetes UK (17/0005587) and the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019).
NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-20011), the MRC Integrative Epidemiology Unit (MC_UU_12013/3) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169).
GDS works in a unit funded by the UK Medical Research Council (MC_UU_00011/1) and the University of Bristol.
TGR and ES work within the Medical Research Council Integrative Epidemiology Unit at the University of Bristol (MC_UU_00011/1). TGR is a UKRI Innovation Research Fellow (MR/S003886/1).
KKT is supported by Cancer Research UK (PPRCPJT\100005)
Information on consortia funding is included in the supplementary material.
Disclaimer Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization.
Data Availability
The summary statistics used in this study are contained in the supplementary materials. The summary-level GWAS data on outcomes used in this study are available following an application to the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO).
